The global neuropathic pain treatment market is estimated to grow at a CAGR of nearly 5.8% during the forecast period. The major factors contributing to the growth of the market include increasing prevalence of diabetes and rising incidences of spinal cord injury. As per the data published by the National Spinal Cord Injury Statistical Center, as of 2019, in the US, the annual incidence of spinal cord injury is approximately 54 cases per one million people, or nearly 17,730 new spinal cord injury cases each year. As of 2019, the estimated number of individuals suffering from spinal cord injury in the US is nearly 291,000. Nearly 78% of new incidences were reported among males. 

Free Sample Copy @ https://www.omrglobal.com/request-sample/neuropathic-pain-treatment-market

Based on the effectiveness, tricyclic antidepressants tend to work effectively as compared to anticonvulsant (gabapentin). The most commonly used tricyclic antidepressants to treat neuropathic pain include desipramine, amitriptyline, nortriptyline, and imipramine. These drugs are effective norepinephrine reuptake inhibitors and thus, majorly supports in the treatment of neuropathic pain. The most common side-effect of tricyclic antidepressants includes constipation, dry mouth, somnolence, memory impairment, and weight gain. Less common side effects include cardiac arrhythmias, urinary retention, blurred vision, and orthostatic hypotension.

A Full Report of Global Neuropathic Pain Treatment Market is Available at:
https://www.omrglobal.com/industry-reports/neuropathic-pain-treatment-market

Some common medications and patches are used to treat neuropathic pain caused by spinal cord injury include gabapentin (Neurontin), amitriptyline (Elavil), pregabalin (Lyrica), and lidocaine (Lidoderm). Lidocaine patches are utilized for pain relief from post-herpetic neuralgia. The patch works by stopping nerves from transmitting pain signals. Pregabalin (Lyrica) is an anticonvulsant drug which is indicated for the treatment of epilepsy and neuropathic pain. Pregabalin is a substitute treatment for patients with neuropathic pain that has not responded to other drug alternatives. Additionally, innovations in neurostimulation devices will likely offer an opportunity for more reliable and efficient treatment of neuropathic pain. 

Global Neuropathic Pain Treatment Market – Segmentation
By Application 
Food and Beverages
Chemical
Pharmaceutical
Others
Global Neuropathic Pain Treatment Market – Segmentation by Region 
North America 
United States
Canada
Europe
Germany
United Kingdom
France
Spain
Italy
Rest of Europe
Asia-Pacific 
China
Japan
India
Rest of Asia-Pacific
Rest of the World

Company Profiles

Abbott Laboratories
Acorda Therapeutics, Inc.
Assertio Therapeutics, Inc. 
Astellas Pharma Inc.
AstraZeneca plc
Biogen Inc.
BioIntervene, Inc.
Boston Scientific Corp.
Cipla Ltd.
Dr. Reddy’s Laboratories Ltd.
Eli Lilly and Co.
GlaxoSmithKline plc
Glenmark Pharmaceuticals Ltd.
Grünenthal GmbH 
Johnson & Johnson Services, Inc.
Lexicon Pharmaceuticals, Inc.
Lupin Ltd.
Medtronic plc
Pfizer Inc.
Sanofi S.A.
Teva Pharmaceutical Industries Ltd.

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/neuropathic-pain-treatment-market

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

Media Contact:

Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: [email protected] 
Contact no: +91 780-304-0404